Literature DB >> 28286568

Immunotherapy in pancreatic cancer treatment: a new frontier.

Komal Thind1, Leslie J Padrnos2, Ramesh K Ramanathan2, Mitesh J Borad3.   

Abstract

Pancreatic cancer is a highly aggressive and lethal cancer characterized by high invasiveness, local and extensive dissemination at time of diagnosis and resistance to treatment. Few therapies have shown efficacy in the past and even standard of care therapies yield only modest improvements in the mortality of patients with advanced or metastatic disease. Efforts have been undertaken to study the pancreatic tumor microenvironment and have established its complex and immunosuppressive nature which could explain the high resistance to chemotherapy. Novel therapies targeting the tumor microenvironment with an aim to decrease this resistance, improve immune tolerance and increase the efficacy of the current treatment have shown some promising preliminary results in preclinical and clinical trials. We review the current advances in the field of immunotherapy and their effectiveness as a potential treatment strategy in the pancreatic cancer.

Entities:  

Keywords:  adoptive cellular immunotherapy; cancer vaccines; immunotherapy; pancreatic cancer

Year:  2016        PMID: 28286568      PMCID: PMC5330603          DOI: 10.1177/1756283X16667909

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN: 1756-283X            Impact factor:   4.409


  129 in total

1.  Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

Authors:  Dung T Le; Andrea Wang-Gillam; Vincent Picozzi; Tim F Greten; Todd Crocenzi; Gregory Springett; Michael Morse; Herbert Zeh; Deirdre Cohen; Robert L Fine; Beth Onners; Jennifer N Uram; Daniel A Laheru; Eric R Lutz; Sara Solt; Aimee Luck Murphy; Justin Skoble; Ed Lemmens; John Grous; Thomas Dubensky; Dirk G Brockstedt; Elizabeth M Jaffee
Journal:  J Clin Oncol       Date:  2015-01-12       Impact factor: 44.544

2.  Reversal of the TCR stop signal by CTLA-4.

Authors:  Helga Schneider; Jos Downey; Andrew Smith; Bernd H Zinselmeyer; Catherine Rush; James M Brewer; Bin Wei; Nancy Hogg; Paul Garside; Christopher E Rudd
Journal:  Science       Date:  2006-08-24       Impact factor: 47.728

Review 3.  Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma.

Authors:  Matthew Weinstock; David McDermott
Journal:  Ther Adv Urol       Date:  2015-12

4.  Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer.

Authors:  B T Brett; S C Smith; C V Bouvier; D Michaeli; D Hochhauser; B R Davidson; T R Kurzawinski; A F Watkinson; N Van Someren; R E Pounder; M E Caplin
Journal:  J Clin Oncol       Date:  2002-10-15       Impact factor: 44.544

5.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

6.  Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model.

Authors:  Hidenobu Ishizaki; Edwin R Manuel; Guang-Yun Song; Tumul Srivastava; Sabrina Sun; Don J Diamond; Joshua D I Ellenhorn
Journal:  Cancer Immunol Immunother       Date:  2010-10-20       Impact factor: 6.968

7.  T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice.

Authors:  Markus Chmielewski; Olga Hahn; Gunter Rappl; Michael Nowak; Ingo H Schmidt-Wolf; Andreas A Hombach; Hinrich Abken
Journal:  Gastroenterology       Date:  2012-06-27       Impact factor: 22.682

8.  Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer.

Authors:  Ramesh K Ramanathan; Kenneth M Lee; John McKolanis; Elizabeth Hitbold; Wolfgang Schraut; Arthur J Moser; Elizabeth Warnick; Theresa Whiteside; Jennifer Osborne; Hyoung Kim; Roger Day; Monica Troetschel; Olivera J Finn
Journal:  Cancer Immunol Immunother       Date:  2004-09-14       Impact factor: 6.968

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

10.  Overexpression of B7-H1 correlates with malignant cell proliferation in pancreatic cancer.

Authors:  Xiao Song; Junwei Liu; Yi Lu; Hongchuan Jin; Dongsheng Huang
Journal:  Oncol Rep       Date:  2013-12-31       Impact factor: 3.906

View more
  37 in total

Review 1.  The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.

Authors:  Federico Nichetti; Antonio Marra; Francesca Corti; Alessandro Guidi; Alessandra Raimondi; Natalie Prinzi; Filippo de Braud; Sara Pusceddu
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

Review 2.  Use of nano engineered approaches to overcome the stromal barrier in pancreatic cancer.

Authors:  Huan Meng; Andre E Nel
Journal:  Adv Drug Deliv Rev       Date:  2018-06-26       Impact factor: 15.470

3.  Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer.

Authors:  Jun Zhao; Zhilan Xiao; Tingting Li; Huiqin Chen; Ying Yuan; Y Alan Wang; Cheng-Hui Hsiao; Diana S-L Chow; Willem W Overwijk; Chun Li
Journal:  ACS Nano       Date:  2018-09-21       Impact factor: 15.881

4.  Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapy.

Authors:  Jingjing Sun; Zhuoya Wan; Yichao Chen; Jieni Xu; Zhangyi Luo; Robert A Parise; Dingwei Diao; Pengfei Ren; Jan H Beumer; Binfeng Lu; Song Li
Journal:  Acta Biomater       Date:  2020-01-28       Impact factor: 8.947

5.  HHLA2 is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival.

Authors:  Han Yan; Wanglong Qiu; Anne K Koehne de Gonzalez; Ji-Shu Wei; Min Tu; Chun-Hua Xi; Ye-Ran Yang; Yun-Peng Peng; Wei-Yann Tsai; Helen E Remotti; Yi Miao; Gloria H Su
Journal:  Cancer Lett       Date:  2018-11-14       Impact factor: 8.679

Review 6.  Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.

Authors:  Clara S Mundry; Kirsten C Eberle; Pankaj K Singh; Michael A Hollingsworth; Kamiya Mehla
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-06-21       Impact factor: 10.680

7.  Macrophage-Derived Neuropilin-2 Exhibits Novel Tumor-Promoting Functions.

Authors:  Sohini Roy; Arup K Bag; Samikshan Dutta; Navatha Shree Polavaram; Ridwan Islam; Samuel Schellenburg; Jasjit Banwait; Chittibabu Guda; Sophia Ran; Michael A Hollingsworth; Rakesh K Singh; James E Talmadge; Michael H Muders; Surinder K Batra; Kaustubh Datta
Journal:  Cancer Res       Date:  2018-08-15       Impact factor: 12.701

Review 8.  Pancreatic Cancer and Immunotherapy: Resistance Mechanisms and Proposed Solutions.

Authors:  Elaine Tan; Bassel El-Rayes
Journal:  J Gastrointest Cancer       Date:  2019-03

9.  Adjuvant therapeutic strategies for resectable pancreatic adenocarcinoma.

Authors:  Nikhil Yegya-Raman; Mihir M Shah; Miral S Grandhi; Elizabeth Poplin; David A August; Timothy J Kennedy; Usha Malhotra; Kristen R Spencer; Darren R Carpizo; Salma K Jabbour
Journal:  Ann Pancreat Cancer       Date:  2018-08-06

Review 10.  Focused ultrasound for immuno-adjuvant treatment of pancreatic cancer: An emerging clinical paradigm in the era of personalized oncotherapy.

Authors:  Ezekiel Maloney; Tanya Khokhlova; Venu G Pillarisetty; George R Schade; Elizabeth A Repasky; Yak-Nam Wang; Lorenzo Giuliani; Matteo Primavera; Joo Ha Hwang
Journal:  Int Rev Immunol       Date:  2017-09-29       Impact factor: 5.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.